300831-03-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-CARBOXY-2-ISOPROPYLAMINOTHIAZOLE HYDROBROMIDE is used as a research compound for exploring its therapeutic potential in the development of new medications. Its diverse pharmacological effects make it a valuable tool in the advancement of treatments for a range of medical conditions.
Used in Anti-inflammatory Applications:
In the field of inflammation management, 4-CARBOXY-2-ISOPROPYLAMINOTHIAZOLE HYDROBROMIDE is used as an anti-inflammatory agent. It is leveraged for its ability to mitigate inflammation, which is crucial in the treatment of various inflammatory conditions.
Used in Analgesic Applications:
For pain management, 4-CARBOXY-2-ISOPROPYLAMINOTHIAZOLE HYDROBROMIDE is utilized as an analgesic agent. Its capacity to alleviate pain makes it a promising option for the treatment of pain-related conditions.
Used in Neuroprotective Applications:
In the realm of neurology, 4-CARBOXY-2-ISOPROPYLAMINOTHIAZOLE HYDROBROMIDE is employed as a neuroprotective agent. Its potential to protect neurons and mitigate neuronal damage positions it as a candidate for the treatment of neurodegenerative diseases and conditions involving neuronal injury.
Used in Anticonvulsant Applications:
4-CARBOXY-2-ISOPROPYLAMINOTHIAZOLE HYDROBROMIDE is used as an anticonvulsant agent in the treatment of seizure disorders. Its properties in reducing the frequency and severity of seizures make it a valuable asset in epilepsy management and other conditions characterized by abnormal electrical activity in the brain.

InChI:InChI=1/C7H10N2O2S.BrH/c1-4(2)8-7-9-5(3-12-7)6(10)11;/h3-4H,1-2H3,(H,8,9)(H,10,11);1H

Upstream product

• 1719-76-2 1-isopropylthiourea 
• 1113-59-3 bromopyruvic acid 

Relevant academic research and scientific papers

Macrocyclic Inhibitors of Hepatitis C Virus

Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR1, NHS(═O)pR2, NHR3, NRaRb, C(═O)NHR3 or C(═O)NRaRb wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl or NRaRb; R3 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, —OC1-C6alkyl, —OC0-C3alkylenecarbocyclyl, —OC0-C3alkyleneheterocyclyl; wherein any alkyl, carbocyclyl or heterocycylyl in R1, R2 or R3 are optionally substituted p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Ry and Ry′ are independently C1-C6alkyl; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; W is —CH2—, —O—, —OC(═O)NH—, —OC(═O)—, —S—, —NH—, —NRa, —NHS(═O)2—, —NHC(=0)NH— or —NHC(═O)—, —NHC(═S)NH— or a bond; R8 is an optionally substituted ring system containing 1 or 2 saturated, partially saturated or unsaturated carbo or heterocyclic rings have utility in the inhibition of NS-3 serine proteases, such as flavivirus infections.

Macrocylic Inhibitors of Hepatitis C Virus

Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(═O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl;R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl;p is independently 1 or 2;n is 3, 4, 5 or 6; — denotes an optional double bond;L is N or CRz; Rz is H or forms a double bond with the asterisked carbon;Rq is H or when L is CRz, Rq can also be C1-C6alkyl;Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl;R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl;R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV

HCV NS-3 serine protease inhibitors

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is

HCV NS-3 serine protease inhibitors

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, of formula: wherein A is

Practical synthesis of 2-(2-isopropylaminothiazol-4-yl)-7-methoxy-1H- quinolin-4-one: Key intermediate for the synthesis of potent HCV NS3 protease inhibitor BILN 2061

Herein we describe the development of an efficient, safe and practical process for the synthesis of 7-methoxy-2-(2-amino-4-thiazolyl)quinoline. Our new process allowed for a more convergent approach and eliminates the use of potentially dangerous reagents such as diazomethane used in the previous discovery approach. Georg Thieme Verlag Stuttgart.

HCV NS-3 SERINE PROTEASE INHIBITORS

Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.